

IDS Form PTO/SB/08: Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number		10/762,796	
Filing Date		January 22, 2004	
Inventor Name		Joseph Tucker	
Art Unit		1634	
Examiner Name		Not Yet Assigned	
Attorney Docket Number		09741.0004-00000	

Sheet 1 of 5

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
ESO		US-5,219,888	06/15/1993	Katocs, Jr. et al.	
		US-5,580,722	12/03/1996	Foulkes et al.	
		US-5,641,755	06/24/1997	Weichselbaum et al.	
		US-5,721,096	02/24/1998	Karathanasis et al.	
		US-5,747,536	05/05/1998	Cavazza	
		US-2003/0166281	09/04/2003	Foulkes et al.	
		US-2004/0235888	11/25/2004	Yamamori et al.	
		US-2004/0242615	12/02/2004	Yamamori et al.	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
ESO		CA 2070058	12/01/1992	Gadski et al.		
		CN 1386742	12/25/2002	Bangqlang et al.		
		EP 0 167 115 A2	01/08/1986	Punicelli		
		EP 0 256 999 A2	02/24/1988	Calvani et al.		
		EP 0 773 020	05/14/1997	Cavazza		
		EP 1 336 602 A2	08/20/2003	Scaramuzzino		
		FR 2735366	06/15/1995	Uclaf Roussel		
		FR 2737662	08/08/1995	Berzaghi et al.		
		GB 2043443	10/08/1980	Cavazza		
		WO 94/12463	06/09/1994	Arena		
		WO 95/30641	11/16/1995	Del Soldato et al.		
		WO 00/72838	12/07/2000	Eek et al.		
		WO 01/12584	02/22/2001	Del Soldato		
		WO 01/16120	03/08/2001	Brooks et al.		
		WO 01/66088	09/13/2001	Holmberg et al.		
		WO 01/98286	12/27/2001	Garvey et al.		
		WO 02/18355	03/07/2002	Brooks et al.		
		WO 02/074282	09/26/2002	Siekman et al.		
		WO 03/022249	03/20/2003	Holmberg		
		WO 03/080029	10/02/2003	Morein et al.		
		WO 03/084550	10/16/2003	Del Soldato		

/Eric Olson/

08/15/2006

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application Number		10/762,796
				Filing Date		January 22, 2004
				First Named Inventor		Joseph Tucker
				Art Unit		1634
				Examiner Name		Not Yet Assigned
Sheet	2	of	5	Attorney Docket Number		09741.0004-00000

FOREIGN PATENT DOCUMENTS					
ESO		WO 2004/000273	12/31/2003	Del Soldato et al.	
ESO		WO 2004/000300	12/31/2003	Del Soldato et al.	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		Translation ²
ESO		Adam et al., "Carbon-Carbon Bond Cleavage of the [2.2]Paracyclophane Radical Cation Generated by Electron Transfer Oxidation with Cerium(IV) Ammonium Nitrate," <i>Chem. Ber.</i> 127:875-879 (1994)		
		Aggarwal et al., "Role of Resveratrol in Prevention and Therapy of Cancer: Preclinical and Clinical Studies," <i>Anticancer Res.</i> 24:2783-2840 (2004)		
		Ahn et al., "Epigallocatechin-3 Gallate Selectively Inhibits the PDGF-BB-induced Intracellular Signaling Transduction Pathway in Vascular Smooth Muscle Cells and Inhibits Transformation of <i>sis</i> -transfected NIH 3T3 Fibroblasts and Human Glioblastoma Cells (A172)," <i>Mol. Biol. Cell</i> 10:1093-1104 (1999)		
		Bai et al., "Genistein-induced Changes in Gene Expression in Panc 1 Cells at Physiological Concentrations of Genistein," <i>Pancreas</i> 29:93-98 (2004)		
		Borradaile et al., "Soya Phytoestrogens, Genistein and Daidzein, Decrease Apolipoprotein B Secretion from HepG2 Cells Through Multiple Mechanisms," <i>Biochem. J.</i> 366:531-539 (2002)		
		Boschi et al., "New Potential Uroselective NO-Donor α 1-Antagonists," <i>J. Med. Chem.</i> 46:3762-3765 (2003)		
		Brunet et al., "Binding of Catechin and Grape Seed Procyanidins to Human and Rat Plasma Proteins," <i>Bull. O.I.V.</i> 74(843-844):364-376 (2001)		
		Burgaud et al., "Nitric-Oxide Releasing Molecules: A New Class of Drugs with Several Major Indications," <i>Curr. Pharma. Des.</i> 8:201-213 (2002)		
		Cirino et al., "Inhibition of Inducible Nitric Oxide Synthase Expression By Novel Nonsteroidal Anti-Inflammatory Derivatives With Gastrointestinal-Sparing Properties," <i>Br. J. Pharmacol.</i> 117:1421-1426 (1996)		
		Clarkson et al., "Inhibition of Postmenopausal Atherosclerosis Progression: a Comparison of the Effects of Conjugated Equine Estrogens and Soy Phytoestrogens," <i>J. Clin. Endocrinol. Metab.</i> 86:41-47 (2001)		
		Dahshti et al., "Concurrent Inductions of Avian Hepatic Lipogenesis, Plasma Lipids, and Plasma Apolipoprotein B By Estrogen," <i>J. Lipid Res.</i> 24:368-380 (1983)		
		Giller et al., "Regulation of Human Apolipoprotein A-1 Expression in Caco-2 and HepG2 Cells by All-trans and 9-cis Retinoic Acids," <i>J. Lipid Res.</i> 36:1021-1028 (1995)		
		Goldberg et al., "Beyond Alcohol: Beverage Consumption and Cardiovascular Mortality," <i>Clin. Chim Acta</i> 237:155-187 (1995)		
		Grech et al., "Novel Ca^{2+} -ATPase Inhibitors from the Dried Root Tubers of <i>Polygonum Multiflorum</i> ," <i>J. Nat. Prod.</i> 37:1682-1687 (1994)		
		Grimes et al., "Cholinergic Stimulation of Early Growth Response-1 DNA Binding Activity Requires Protein Kinase C and Mitogen-Activated Protein Kinase Kinase Activation and Is Inhibited By Sodium Valproate in SH-SY5Y Cells," <i>J Neurochem.</i> 73:1384-1392 (1999)		
		Halling, "Altered Patterns of Proteins Released <i>In Vitro</i> From Oviductal and Uterine Tissue From Adult Female Mice Treated Neonatally With Diethylstilbestrol," <i>J. Steroid</i>		

/Eric Olson/

08/15/2006

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application Number	10/762,796	
				Filing Date	January 22, 2004	
				First Named Inventor	Joseph Tucker	
				Art Unit	1634	
				Examiner Name	Not Yet Assigned	
Sheet	3	of	5	Attorney Docket Number		09741.0004-00000

NON PATENT LITERATURE DOCUMENTS			
ESO		Biochem. Mol. Biol. 44:227-237 (1993)	
		Inamori et al., "The Biological Activity of 3,4-O-Isopropylidene-3,3',4,5'-tetrahydroxystilbene," <i>Chem. Pharm. Bull.</i> 33:2904-2909 (1985)	
		Jiang et al., "Cardiovascular Protective Effects of Synthetic Isoflavone Derivatives in Apolipoprotein-E-Deficient Mice," <i>J. Vascular Res.</i> 40:276-284 (2003)	
		Jung et al., "Naringin Supplementation Lowers Plasma Lipids and Enhances Erythrocyte Antioxidant Enzyme Activities in Hypercholesterolemic Subjects," <i>Clin. Nutr.</i> 22:561-568 (2003)	
		Kudzma et al., "Effects of Estrogen Administration on the Lipoproteins and Apoproteins of the Chicken," <i>Biochim. Biophys. Acta.</i> 572:257-268 (1979)	
		Lamon-Fava, "Genistein Activates Apolipoprotein A-I Gene Expression in the Human Hepatoma Cell Line Hep G2," <i>J. Nutr.</i> 130:2489-2492 (2000)	
		Law et al., "Aortic Endothelial Cells Damaged by a Nitric Oxide Donor and Protected by Flavonoids," <i>Life Sci.</i> 64:199-204 (1999)	
		Lin et al., "Estrogen Regulation of Yolk and Non-Yolk Protein Synthesis in the Avian Liver. An Immunocytochemical Study," <i>Differentiation</i> 18:105-114 (1981)	
		Lin et al., "Effects of Estrogen on Specific Protein Synthesis in the Cockerel Liver: an Immunocytochemical Study on Major Apoproteins in Very Low Density and High Density Lipoproteins and Albumin," <i>Endocrinology</i> 107:70-75 (1980)	
		Luo et al., "Influences of 3,4,5-trihydroxystilbene-3-B-mono-D-glucoside on Beat Rate and Injury of Cultured Newborn Rat Myocardial Cells," <i>Acta Pharmacologica Sinica</i> 11:147-150 (1990)	
		Matsuura et al., "Positional Reactivity of Acylpolymethylbenzenes in Electrophilic Substitution," <i>Bull. Chem. Soc. Jpn.</i> 67:757-765 (1994)	
		Neuhaus et al., "Inhibition of the Vascular-Endothelial Growth Factor-Induced Intracellular Signaling and Mitogenesis of Human Endothelial Cells by Epigallocatechin-3 Gallate," <i>Eur. J. Pharmacol.</i> 483:223-227 (2004)	
		Nikander et al., "Effects of Isolated Isoflavonoids on Lipids, Lipoproteins, Insulin Sensitivity, and Ghrelin in Postmenopausal Women," <i>J. Clin. Endocrinol. Metab.</i> 89:3567-3572 (2004)	
		Pace-Asciak et al., "The Red Wine Phenolics trans-Resveratrol and Quercetin Block Human Platelet Aggregation and Eicosanoid Synthesis: Implications for Protection Against Coronary Heart Disease," <i>Clinica Chimica Acta</i> 235:207-219 (1995)	
		Quinoñes et al., "The <i>egr-1</i> Gene Is Induced By DNA-Damaging Agents and Non-Genotoxic Drugs in Both Normal and Neoplastic Human Cells," <i>Life Sci.</i> 72:2975-2992 (2003)	
		Ragione et al., "Antioxidants Induce Different Phenotypes by a Distinct Modulation of Signal Transduction," <i>FEBS Lett.</i> 532:289-294 (2002)	
		Ragione et al., "p21Cip1 Gene Expression is Modulated by Egr1: A Novel Regulatory Mechanism Involved in the Resveratrol Antiproliferative Effect," <i>J. Biol. Chem.</i> 278:23360-23368 (2003)	
		Rampa et al., "Fluorenone and Benzophenone 1,4-Dihydropyridine Derivatives With Cardiodepressant Activity," <i>Arzneim.-Forsch./Drug Res.</i> 42:1284-1287 (1992)	
		Saadeddin et al., "Pharmacokinetics of the Time-Dependent Elimination of All-Trans-Retinoic Acid in Rats," <i>AAAPS PharmSci</i> 6:1-9 (2004)	
↓		Sanders et al. "Moderate Intakes of Intact Soy Protein Rich in Isoflavones Compared With Ethanol-Extracted Soy Protein Increase HDL But Do Not Influence Transforming Growth Factor $\beta(1)$ Concentrations and Hemostatic Risk Factors For Coronary Heart	

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/762,796
				Filing Date	January 22, 2004
				First Named Inventor	Joseph Tucker
				Art Unit	1634
				Examiner Name	Not Yet Assigned
Sheet	4	of	5	Attorney Docket Number	09741.0004-00000

NON PATENT LITERATURE DOCUMENTS			
ESO		Disease in Healthy Subjects" <i>Am. J. Clin. Nutr.</i> 76:373-377 (2002)	
		Suzuki et al., "Anomalous Products Obtained by Nitration of Pentamethylbenzene, Pentaethylbenzene, and Some Mixed Penta-alkylbenzenes," <i>Bull. Chem. Soc. Jpn.</i> 43:473-480 (1970)	
		Suzuki et al., "An Interpretation of the Puzzling Dichotomy of the Reaction Modes Observed During the Side-chain Nitration of Alkylaromatics with HNO ₃ /CH ₂ Cl ₂ and HNO ₃ /(CH ₃ CO) ₂ O," <i>Chem. Lett.</i> 5:891-894 (1987)	
		Suzuki et al., "Synthesis of 7,8-Dihydroxy-5-hydroxymethyl-2-phenyl-chroman-4-one; the Aglycon of Actinoflavoside," <i>SYNLETT</i> 1:0116-0118 (2004)	
		Taylor et al., "Beneficial Effects of a Novel Thyromimetic on Lipoprotein Metabolism," <i>Molecular Pharmacology</i> 52:542-547 (1997)	
		Taylor et al., "Glucocorticoid Increases Rat Apolipoprotein A-1 Promoter Activity," <i>J. Lipid Res.</i> 37:2232-2243 (1996)	
		Theriault et al., "Modulation of Hepatic Lipoprotein Synthesis and Secretion By Taxifolin, a Plant Flavonoid," <i>J. Lipid Res.</i> 41:1969-1979 (2000)	
		Usui et al., "Estrogen Treatment of Prostate Cancer Increases Triglycerides in Lipoproteins as Demonstrated by HPLC and Immunoseparation Techniques," <i>Clin. Chim. Acta</i> 317:133-143 (2002)	
		Wallace et al., "Novel Nonsteroidal Anti-Inflammatory Drug Derivatives With Markedly Reduced Ulcerogenic Properties in the Rat," <i>Gastroenterology</i> 107:173-179 (1994)	
		Walle et al., "High Absorption But Very Low Bioavailability of Oral Resveratrol in Humans," <i>Drug Metabolism and Disposition</i> 32:1377-1382 (2004)	
		Wang et al., "Reducing Effect of 3,4',5-trihydroxystilbene-3-B-mono-D-glycoside on Arterial Thrombosis Induced by Vascular Endothelial Injury," <i>Acta Pharmacologica Sinica</i> 16(3):159-162 (1995)	
		Zhang et al., "Influence of 3,4',5-trihydroxystilbene-3-B-mono-D-glycoside on Vascular Endothelial Epoprostenol and Platelet Aggregation," <i>Acta Pharmacologica Sinica</i> 16:265-268 (1995)	
		Chemical Abstract DN 170:287654; also cited as CN 1386742.	
		Chemical Abstract DN 126:220717; also cited as FR 2735366.	
		Chemical Abstract DN 126:301793; also cited as FR 2737662.	
		Office Action dated June 7, 2005, in co-pending Application No. 10/222,013, Attorney Docket No. 09741.0002-00000, Title: The Use of Resveratrol to Regulate Expression of Apolipoprotein AI, Filed: August 15, 2002.	
		Office Action dated November 15, 2005, in co-pending Application No. 10/222,013, Attorney Docket No. 09741.0002-00000, Title: The Use of Resveratrol to Regulate Expression of Apolipoprotein AI, Filed: August 15, 2002.	
		International Search Report for PCT Publication No. WO 2004/016255, which claims priority to co-pending Application No. 10/222,013, Attorney Docket No.: 09741.0002-00000, Title: The Use of Resveratrol to Regulate Expression of Apolipoprotein AI, Filed: August 15, 2002.	
		International Search Report for International Application No. PCT/CA2004/001805 priority application for co-pending U.S. Application No. 10/762,796, Attorney Docket No.: 09741.0006-00304, Title: Nitric Oxide Donating Derivatives for the Treatment of Cardiovascular Disorders, Filed: October 7, 2004.	
▼		International Search Report for International Application No. PCT/CA2004/001818 priority application for co-pending U.S. Application No. 10/807,800, Attorney Docket	

IDS Form PTO/SB/08: Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known			
				Application Number		10/762,796	
				Filing Date		January 22, 2004	
				First Named Inventor		Joseph Tucker	
				Art Unit		1634	
				Examiner Name		Not Yet Assigned	
Sheet	5	of	5	Attorney Docket Number		09741.0004-00000	

NON PATENT LITERATURE DOCUMENTS			
ESO		No.: 09741.0007-00304, Title: Treatment of Diseases Associated with the EGR-1 Enhancer Element, Filed: October 8, 2004.	

Examiner Signature	/Eric Olson/	Date Considered	08/15/2006
-----------------------	--------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY DOCKET NO. 22918/6-CIP		SERIAL NO. 10/762,796			
				APPLICANT(S): Tucker et al.					
				FILING DATE: January 22, 2004		ART UNIT: 1634			
UNITED STATES PATENT DOCUMENTS									
EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR		
ESO		5,039,705	Aug. 13, 1991	Keefer et al.	514	611			
		5,145,839	Sep. 8, 1992	Beljanski	514	27			
		5,155,137	Oct. 13, 1992	Keefer et al.	514	611			
		5,208,233	May 4, 1993	Keefer et al.	514	231.8			
		5,405,919	April 11, 1995	Keefer et al.	525	377			
		5,422,373	June 6, 1995	Franzmann	514	598			
		5,763,414	June 9, 1998	Bok et al.	514	27			
		5,877,009	March 2, 1999	Zannis et al.	435	320.1			
		5,877,208	March 2, 1999	Bok et al.	514	456			
		5,973,011	Oct. 26, 1999	Noack et al.	514	742			
		5,994,061	Nov. 30, 1999	Tam et al.	435	6			
		6,022,901	Feb. 8, 2000	Goodman	514	733			
		6,048,903	April 11, 2000	Toppo	514	733			
		6,080,780	June 27, 2000	Paladini et al.	514	456			
		6,087,353	July 11, 2000	Stewart et al.	514	182			
		6,096,364	Aug. 1, 2000	Bok et al.	426	590			
		6,103,733	Aug. 15, 2000	Bachmann et al.	514	277			
		6,120,994	Sep. 19, 2000	Tam	435	6			
		6,133,241	Oct. 17, 2000	Bok et al.	514	27			
		6,133,311	Oct. 17, 2000	Bok et al.	514	453			
Examiner: /Eric Olson/				Date: 08/15/2006					

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY DOCKET NO. 22918/6-CIP		SERIAL NO. 10/762,796	
				APPLICANT(S): Tucker et al.			
				FILING DATE: January 22, 2004		ART UNIT: 1634	
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR
ESO		6,165,984	Dec. 26, 2000	Bok et al.	514	27	
		6,165,998	Dec. 26, 2000	Wobbe et al.	514	150	
		6,203,818	March 20, 2001	Vester	424	569	
		6,211,247	April 3, 2001	Goodman	514	733	
		6,221,357	April 24, 2001	Bok et al.	424	195.1	
		6,232,336	May 15, 2001	Hrabie et al.	514	402	
		6,414,037	July 2, 2002	Pezzuto et al.	514	733	
		6,541,522	April 1, 2003	Inman et al.	514	568	08/02/01
		6,548,548	April 15, 2003	Campbell et al.	514	617	12/06/01
		6,617,122	Sep. 9, 2003	Hayden et al.	435	19	03/15/00
		6,753,346	June 22, 2004	Shinkai et al.	514	489	05/22/02
		2001/0002264	May 31, 2001	Bok et al.	424	736	12/28/00
		2001/0006978	July 5, 2001	Bok et al.	514	456	01/24/01
		2001/0014357	Aug. 16, 2001	Bok et al.	424	736	02/12/01
		2001/0014669	Aug. 16, 2001	Bok et al.	514	27	03/13/01
		2001/0055627	Dec. 27, 2001	Gibrie et al.	424	736	01/12/00
		2003/0171429	Sep. 11, 2003	Chen et al.	514	475	12/06/00
		2003/0199566	Oct. 23, 2003	Bok et al.	514	397	12/04/02
Examiner: /Eric Olson/				Date: 08/15/2006			

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY DOCKET NO. 22918/6-CIP	SERIAL NO. 10/762,796
		APPLICANT(S): Tucker et al.	
		FILING DATE: January 22, 2004	ART UNIT: 1634
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)			
ESO		Barter, P.J. et al., "Molecular Mechanisms of Reverse Cholesterol Transport", <i>Current Opinion in Lipidology</i> 7:82 – 87, (1996)	
		Bertele et al., "Platelet Thromboxane Synthetase Inhibitors with Low Doses of Aspirin: Possible Resolution of the "Aspirin Dilemma"; <i>Science</i> 220 517 (1983)	
		Bertelli, A. et al., "Plasma and Tissue Resveratrol Concentrations and Pharmacological Activity", <i>Drugs Exptl. Clin. Res.</i> 24:133-138 (1998)	
		Casper, R.F. et al., "Resveratrol Has Antagonist Activity on the Aryl Hydrocarbon Receptor: Implications for Prevention of Dioxin Toxicity", <i>Molecular Pharmacology</i> 56:784-790 (1999)	
		Cavallaro, A. et al., "Effect of Resveratrol on Some Activities of Isolated and in Whole Blood Human Neutrophils", <i>Physiol. Res.</i> 52:555 (2003)	
		Cena, C. et al., "Antiinflammatory, Gastrosparing, and Antiplatelet Properties of New NO-Donor Esters of Aspirin", <i>J. Med. Chem.</i> 46:747 (2003)	
		Chang, Thomas K. H. et al., "Differential Inhibition and Inactivation of Human CYP1 Enzymes by <i>trans</i> -Resveratrol: Evidence for Mechanism-Based Inactivation of CYP1A2", <i>The Journal of Pharmacology and Experimental Therapeutics</i> 299:874 (2001)	
		Chanvitayapongs S. et al., "Amelioration of Oxidative Stress by Antioxidants and Resveratrol in PC12 Cells", <i>Neuroreport</i> 8:1499-1502, (1997)	
		Chrysselis, M.C. et al., "Nitric Oxide Releasing Morpholine Derivatives as Hypolipidemic and Antioxidant Agents", <i>J. Med. Chem.</i> 45:5406 (2002)	
		Ferre, "The Biology of Peroxisome Proliferator-Activated Receptors, Relationship With Lipid Metabolism and Insulin Sensitivity" (2004) <i>Diabetes</i> 53 Suppl 1:S43-50	
		Frankel E.N., et al., "Inhibition of Oxidation of Human Low-Density Lipoprotein By Phenolic Substances in Red Wine" <i>Lancet</i> 341:1103-1104, (1993)	
		Gaukroger, K. et al., "Novel Syntheses of Cis and Trans Isomers of Combretastatin A-4", <i>J. Org. Chem.</i> 66:8135-8138 (2001)	
		German, J.B. et al., "The Health Benefits of Wine", <i>Annu. Rev. Nutr.</i> 20:561 (2000)	
		Gidez et al., "Separation and Quantitation of Subclasses of Human Plasma High Density Lipoproteins by a Simple Precipitation Procedure", <i>J. Lipid Res</i> 23 1206-1223 (1982)	
		Haider, von Ursula et al., "Resveratrol Attenuates Vascular Smooth Muscle Cell Hypertrophy and Hyperplasia, Elucidation of Signaling Pathways" (2003)	
		Haneke, Karen E., "Trans-Resveratrol [501-36-0] Review of Toxicological Literature", <i>Nat inst. Environ health sciences contract No. NOI-ES-65402</i> March (2002)	
		Higuchi et al., "Tissue-Specific Expression of Apolipoprotein A-I (ApoA-I) Is Regulated by the 5' - Flanking Region of the Human ApoA-I Gene", <i>Journal of Biological Chemistry</i> , 263(34):18530-18536 (1988)	
		Howitz et al., "Small Molecule Activators of Sirtuins Extend <i>Saccharomyces Cerevisiae</i> Lifespan", <i>Nature</i> 2003 Aug. 24;425(6954):191-6. Epub (2003)	
		Jang, M et al., "Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived From Grapes" <i>Science</i> 275:218-220, (1997)	
Examiner:		/Eric Olson/	Date: 08/15/2006

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY DOCKET NO. 22918/6-CIP	SERIAL NO. 10/762,796
		APPLICANT(S): Tucker et al.	
		FILING DATE: January 22, 2004	ART UNIT: 1634
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)			
ESO		Jayatilake et al., "Kinase Inhibitors From Polygonum Cuspidatum", <i>J. Nat Prod</i> Vol. 56 No.-10 1805-1810 (1993)	
		Kilbourne et al., "Involvement of Early Growth Response Factor Egr-1 in Apolipoprotein AI Gene Transcription", <i>Journal of Biological Chemistry</i> 270(12) 7004-10 (1995)	
		Kim, S. et al., "Design, Synthesis, and Discovery of Novel <i>trans</i> -Stilbene Analogues as Potent and Selective Human Cytochrome P450 1B1 Inhibitors", <i>J. Med. Chem.</i> 45:160-164 (2002)	
		Lamon-Fava, S. et al., "Regulation of apoA-I Gene Expression: Mechanism of Action of Estrogen and Genistein", <i>Journal of Lipid Research</i> 45:106-112 (2004)	
		Latruffe, N. et al., "Molecular Analysis on the Chemopreventive Properties of Resveratrol, A Plant Polyphenol Microcomponent", <i>International Journal of Molecular Medicine</i> 10:755 (2002)	
		Li, B. et al., "Evaluation of Properties of Apigenin and [G- ³ H]Apigenin and Analytic Method Development", <i>Journal of Pharmaceutical Sciences</i> 86(6):721 (1997)	
		Lin, J. K. et al., "Chemoprevention of Cancer and Cardiovascular Disease by Resveratrol", <i>Proc. Natl. Sci. Counc. ROC</i> 23(3):99-106 (1999)	
		Miller N.E., "Associations of High-Density Lipoprotein Subclasses and Apolipoproteins with Ischemic Heart Disease and Coronary Atherosclerosis", <i>American Heart Journal</i> 113(2) 589 - 597, (1987)	
		Miller N.E. et al., "Direct Evidence That Reverse Cholesterol Transport is Mediated by High-Density Lipoprotein in Rabbit", <i>Nature</i> 314 109-111, (1985)	
		Neve B.P. et al., "Role of Peroxisome Proliferator-Activated Receptors (PPAR) in Atherosclerosis", <i>Biochemical Pharmacology</i> , Vol. 60 1245-1250 (2000)	
		Nissen, S.E. et al., "Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients with Acute Coronary Syndromes", <i>Journal of the American Medical Association</i> 290 17:2292 (2003)	
		Otake et al., "Glucuronidation Versus Oxidation of The Flavonoid Galangin By Human Liver Microsomes and Hepatocytes", <i>Drug Metabolism and Disposition</i> , 30 (5) 576-581 (2002)	
		Renaud, S. et al., "Wine, Alcohol, Platelets, and the French Paradox for Coronary Heart Disease", <i>The Lancet</i> 339(8808):1523 (1992)	
		Reynolds et al., "Role of Thromboxane A ₂ /Prostaglandin H ₂ Receptor in the Vasoconstrictor Response of Rat Aorta to Endothelin" <i>J. Pharmacology and Experimental Therapeutics</i> 252 (3) 915 (1990)	
		Rossi A et al., "Inhibition of Nuclear Factor κ B by Prostaglandin A1: An Effect Associated with Heat Shock Transcription Factor Activation", <i>Proc Natl Acad Sci USA</i> (94) 746-750 (1997)	
		Rotondo S. et al., "Effect of <i>Trans</i> -Resveratrol, a Natural Polyphenolic Compound, on Human Polymorphonuclear Leukocyte Function", <i>British Journal of Pharmacology</i> 123:1691-1699, (1998)	
		Soleas, George J. et al., "Resveratrol: A Molecule Whose Time Has Come? And Gone?" <i>Clinical Biochemistry</i> 30(2):91-113, (1997)	
		Tardif et al., "Probucol and Multivitamins in the Prevention of Restenosis After Coronary Angioplasty", <i>New England Journal of Medicine</i> 337(6) 365-367 (1997)	
		Taylor A.H. et al., "Identification of Functional Positive and Negative Thyroid Hormone-Responsive Elements in the Rat Apolipoprotein AI Promoter", <i>Biochemistry</i> ;35(25):8281-8 1996	
		Taylor A.H. et al., "Oestradiol Decreases Rat Apolipoprotein AI Transcription Via Promotor Site B", <i>Journal of Molecular Endocrinology</i> : 25(2): 207-19 (2000)	
Examiner:		/Eric Olson/	Date: 08/15/2006

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY DOCKET NO. 22918/6-CIP	SERIAL NO. 10/762,796
		APPLICANT(S): Tucker et al.	
		FILING DATE: January 22, 2004	ART UNIT: 1634
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)			
ESO		Tessitore, L. et al, "Resveratrol Depresses the Growth of Colorectal Aberrant Crypt Foci by Affecting <i>bax</i> and <i>p21</i> ^{CIP} Expression", <i>Carcinogenesis</i> 21:1619-1622 (2000)	
		Thakkar, K. et al., "Synthesis and Protein-Tyrosine Kinase Inhibitory Activity of Polyhydroxylated Stilbene Analogues of Piceatannol", <i>J. Med. Chem.</i> 36:2950-2955 (1993)	
		Tudan et al., "Selective Inhibition of Protein Kinase C, Mitogen-Activated Protein Kinase, and Neutrophil Activation in Response to Calcium Pyrophosphate Dihydrate Crystals, Formyl-Methionyl-Leucyl-Phenylalanine, and Phorbol Ester by O-(Chloroacetyl-carbamoyl) Fumagillol (AGM-01470; TNP-470)", <i>Biochem. Pharmacol.</i> 58:1869-1880 (1999)	
		Varin et al., "Enzymatic Assay for Flavonoid Sulfotransferase", <i>Anal Biochem</i> 161:176-180 (1987)	
		Wilcox, L. J. et al., "Secretion of Hepatocyte apoB is Inhibited by the Flavonoids, Naringenin and Hesperetin, Via Reduced Activity and Expression of ACAT2 and MTP", <i>Journal of Lipid Research</i> 42:725-734 (2001)	
		Zheng et al., "Activation of Apolipoprotein A1 Gene Expression by Protein Kinase A and Kinase C Through Transcription Factor, Sp1", <i>Journal of Biological Chemistry</i> , 275(41): 31747-54 (2000)	
		Cramer et al., "New Syntheses of Aryl Fluorides and Aryl Fluorosulfonates from Oxyfluorides of Sulfur", <i>J Org. Chem.</i> 26:4164 (1961)	
		Dai et al., "Binding of Nuclear Proteins to the Enhancer Elements of the Rat Apolipoprotein A-I Gene", <i>Eur. J. Biochem.</i> , 190(2):305-10 (1990)	
		Esterbauer, H. et al., "Continuous Monitoring of <i>In Vitro</i> Oxidation of Human Low Density Lipoprotein", <i>Free Radic. Res. Comms</i> , 6(1): 67-75 (1989)	
		Franceschini G. et al., "Reverse Cholesterol Transport: Physiology and Pharmacology", <i>Atherosclerosis</i> 88:99 - 107, (1991)	
		Reynolds et al., "Role of Thromboxane A ₂ /Prostaglandin H ₂ Receptor in the Vasoconstrictor Response of Rat Aorta to Endothelin ¹ ", <i>Journal of Pharmacology and Experimental Therapies</i> 252, 915, (1990)	
		Kuhnle, G. et al., "Resveratrol is Absorbed in the Small Intestine as Resveratrol Glucuronide", <i>Biochemical and Biophysical Research Communications</i> 272:212 (2000)	
		Kulkarni et al., "Quantification of HDL ₂ and HDL ₃ Cholesterol by the Vertical Auto Profile-II (VAP-II) Methodology", <i>J. Lipid Res.</i> 38:2353-64 (1997)	
		Luoma P., "Gene Activation, Apolipoprotein A-I/High Density Lipoprotein, Atherosclerosis Prevention and Longevity", <i>Pharmacology & Toxicology</i> 81 57 - 64, (1997)	
		Marks, Friedrich, "Epidermal Growth Control Mechanisms, Hyperplasia, and Tumor Promotion in the Skin ¹ ", <i>Cancer Research</i> 36 2636 (1976)	
		Mondal et al., "Two-Stage Chemical Oncogenesis in Cultures of C3H/10T1/2 Cells ¹ ", <i>Cancer Research</i> 36:2254-2260 (1976)	
		Murao K. et al., "Effects of Glucose and Insulin on Rat Apolipoprotein A-I Gene Expression", <i>Journal of Biological Chemistry</i> , 273 (30): 188959-65, (1998).	
		Shapiro et al., "Micro Assay for 3-Hydroxy-3-Methylglutaryl-CoA Reductase in Rat Liver and in L-Cell Fibroblasts", <i>Biochemica et Biophysica Acta</i> , 370, 369-377 (1974)	
		Slowing et al., "Anti-Inflammatory Activity of Leaf Extracts of <i>Eugenia Jambos</i> in Rats", <i>Journal of Ethnopharmacology</i> , 43:9-11 (1994)	
		Suryadevara et al., "Association of Abnormal Serum Lipids in Elderly Persons With Atherosclerotic Vascular Disease and Dementia, Atherosclerotic Vascular Disease Without Dementia, Dementia Without Atherosclerotic Vascular Disease, and No Dementia or Atherosclerotic Vascular Disease" <i>J. Gerontol Med. Sci.</i> 58A(9):859-61 (2003)	
Examiner: /Eric Olson/		Date: 08/15/2006	

Examiner: /Eric Olson/	Date: 08/15/2006